- Clinical Trials
- Research News
- Industry Trends
- Agency Actions
- Drug Safety Issues
- Approvals, Launches, & New Indications
- Health Care Reform
Generic Zemplar (Paricalcitol) Launched in U.S.
Active form of vitamin D treats hyperparathyroidism (October 1)
A generic equivalent of Zemplar (paricalcitol) tablets is now available in the U.S. The generic drug was launched on Sept. 30 by Teva Pharmaceutical Industries.
Paricalcitol is an active form of vitamin D used to prevent and treat secondary hyperparathyroidism (increased parathyroid hormone levels) in patients with stage-3 or -4 chronic kidney disease and in stage-5 patients on dialysis.
Marketed by AbbVie Inc., brand-name Zemplar had annual sales of approximately $115 million in the U.S., according to IMS data as of June 30, 2013.
Source: Teva; October 1, 2013.